Ovarian serous tumor

Summary

Ovarian serous tumor (MONDO:0037255) is a cancer and 7 clinical trials. Top therapeutic interventions include auranofin, carboplatin, and gemcitabine. A subtype of ovarian epithelial tumor — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Classification: Cancer
• Clinical trials: 7

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	ovarian serous tumor
Mondo ID	MONDO:0037255
NCIT	C8431
UMLS	C0476122
MedGen	141653
Anatomy (UBERON)	UBERON:0000992
Is cancer (heuristic)	yes

Also known as: ovarian serous neoplasm · ovarian serous tumor · serous neoplasm of ovary · serous neoplasm of the ovary · serous tumor of ovary · serous tumor of the ovary · serous tumour of ovary · serous tumour of the ovary

Disease family

This is a subtype of ovarian epithelial tumor. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › epithelial neoplasm › ovarian epithelial tumor › ovarian serous tumor

Related subtypes (10): ovarian Brenner tumor, ovarian squamous cell neoplasm, ovarian mucinous neoplasm, ovarian seromucinous tumor, ovarian papillary tumor, ovarian mucinous adenofibroma, ovarian adenoma benign, borderline epithelial tumor of ovary, malignant epithelial tumor of ovary, ovarian clear cell tumor

Subtypes (2): borderline ovarian serous tumor, malignant ovarian serous tumor

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 7.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE2	4
PHASE1	2
PHASE3	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT02446600	PHASE3	ACTIVE_NOT_RECRUITING	Testing the Use of A Single Drug (Olaparib) or the Combination of Two Drugs (Cediranib and Olaparib) Compared to the Usual Chemotherapy for Women With Platinum Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
NCT02595892	PHASE2	ACTIVE_NOT_RECRUITING	Gemcitabine Hydrochloride Alone or With M6620 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
NCT05500391	PHASE2	RECRUITING	Assessment of Compliance With Monitoring Conducted by a Physician in Person or by a Nurse in Remote Monitoring
NCT03456700	PHASE2	TERMINATED	Auranofin and Sirolimus in Treating Participants With Ovarian Cancer
NCT03685695	PHASE2	COMPLETED	Physical Activity Monitored by Fitbit Charge 2 in Improving Quality of Life in Participants With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
NCT02520115	PHASE1	COMPLETED	Folate Receptor in Diagnosing Ovarian Cancer Using Serum Samples From Patients With Newly Diagnosed Pelvic Mass or Previously Diagnosed Ovarian Cancer
NCT02627430	PHASE1	WITHDRAWN	Talazoparib and HSP90 Inhibitor AT13387 in Treating Patients With Metastatic Advanced Solid Tumor or Recurrent Ovarian, Fallopian Tube, Primary Peritoneal, or Triple Negative Breast Cancer

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
AURANOFIN	4	1
CARBOPLATIN	4	1
GEMCITABINE	4	1
OLAPARIB	4	1
CEDIRANIB MALEATE	3	1
BERZOSERTIB	2	1
CHEMBL3774645	0	1
CHEMBL4303702	0	1
CHEMBL5279950	0	1
CHEMBL3764816	0	1
CHEMBL5724798	0	1